J.P.S. Sawhney - Concepedia

Author

J.P.S. Sawhney

Also Known As

J P S Sawhney, J. P. S. Sawhney, J. Sawhney, J.P. Sawhney, J.P.S. Sawhney, Jappan Sawhney, Jitendra P S Sawhney, Jitendra P. S. Sawhney, Jitendra P.S. Sawhney, Jitendra Pal Sawhney

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Sir Ganga Ram Hospital National Heart Centre Singapore Thrombosis Research Institute Veterans Health Administration St George's, University of London

About

J.P.S. Sawhney is an author at Sir Ganga Ram Hospital specializing in medicine, cardiovascular disease, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	121
2	Public Health	2	2	43
3	Epidemiology	2	2	43
4	Global Health	1	1	22
5	Cardiovascular Genetics	1	1	22

J.P.S. Sawhney

Publications

841

Citations

H-Index

Page 1

	Year	Citations
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial R. James White, Carlos Jerjes‐Sánchez, G. Meyer, American Journal of Respiratory and Critical Care Medicine	2019	142
Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study Chanchal Chandramouli, Wan Ting Tay, Nurul Sahiddah Binte Salahudin Bamadhaj, PLoS Medicine	2019	118
Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN‐HF Registry Michael R. MacDonald, Wan Ting Tay, Tiew‐Hwa Katherine Teng, Journal of the American Heart Association	2019	114
Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction Jasper Tromp, Shir Lynn Lim, Wan Ting Tay, Diabetes Care	2019	76
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial Frank Cools, Saverio Virdone, J.P.S. Sawhney, The Lancet Haematology ThrombosisPreventive MedicineAt-risk OutpatientsLong CovidThromboprophylactic Low-molecular-weight Heparin	2022	60
Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry Shinya Goto, Pantep Angchaisuksiri, Jean‐Pierre Bassand, Journal of the American Heart Association	2019	54
Effects of Combined Renin–Angiotensin–Aldosterone System Inhibitor and Beta-Blocker Treatment on Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from BIOSTAT-CHF and ASIAN-HF Registries Wouter Ouwerkerk, Tiew‐Hwa Katherine Teng, Jasper Tromp, European Journal of Heart Failure	2020	35
Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia Tiew‐Hwa Katherine Teng, Wan Ting Tay, Mark Richards, Circulation Cardiovascular Quality and Outcomes	2021	33
Rationale, Design, and Baseline Characteristics of the <scp>EPICOR</scp> Asia Study (Long‐<scp>tErm</scp> follow‐<scp>uP</scp> of antithrombotic management patterns In Acute <scp>CORonary</scp> Syndrome patients in Asia) Yong Huo, Stephen W.L. Lee, J.P.S. Sawhney, Clinical Cardiology	2015	30
Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India J.P.S. Sawhney, Shashi Prasad, Manish Sharma, Indian Heart Journal	2019	29

Page 1